| Similar Articles |
|---|
 |
The Motley Fool
January 2, 2012
Sean Williams |
2012 Preview: Aeterna Zentaris Let's look ahead and see what will be driving Aeterna's stock price in 2012.   |
The Motley Fool
November 9, 2011
Sean Williams |
3 Stocks to Get on Your Watchlist It's Watchlist Wednesday, and here's what's on my radar. |
The Motley Fool
August 11, 2011
Sean Williams |
Aeterna Zentaris: Out of Sight, Out of Mind Perifosine, the company's lead cancer drug, hits key milestones. |
The Motley Fool
March 9, 2011
Sean Williams |
10 Small Caps to Rule Them All See if junior miner Golden Star Resources has what it takes to dig up profits for your portfolio. |
The Motley Fool
May 19, 2011
Sean Williams |
Aeterna Zentaris Continues to Deliver Positive Results The most important aspect of Aeterna Zentaris' quarterly filing is its partnership with Yakult Honsha in Japan. |
The Motley Fool
November 11, 2011
Sean Williams |
Aeterna Zentaris Surprises Again A quarterly profit shocks analysts and me alike. |
The Motley Fool
March 9, 2011
Brian Orelli |
Slicing and Dicing Your Way through Drug Development The drug developer announces that it licensed the Japanese rights to perifosine, its lead cancer drug, to Yakult Honsha. |
The Motley Fool
May 31, 2011
David Williamson |
Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin... |
The Motley Fool
July 29, 2011
Brian Orelli |
2 Biotechs, 1 Promising Cancer Drug Perifosine on the home stretch. |
The Motley Fool
August 10, 2007
Toby Shute |
Wish Upon a Golden Star Golden Star Resources has investors hopeful after raising production guidance for the full year. With two promising, open-pit mine properties in Ghana, the future looks bright for this gold mining company. |
The Motley Fool
April 5, 2011
Christopher Barker |
New Gold Buys New Gold New Gold brings new strength to its golden development pipeline. |
The Motley Fool
November 9, 2010
Travis Hoium |
Golden Star Resources Shares Plunged: What You Need to Know Golden Star Resources shares fell 12% today after the company released third-quarter results and an exploration update. |
The Motley Fool
October 6, 2011
Brian Orelli |
Data Published; Back to Waiting Phase 2 data for Aeterna Zentaris and Keryx's perifosine was published, but it's the phase 3 that's important. |
The Motley Fool
December 23, 2011
Selena Maranjian |
3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick. |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies. |
The Motley Fool
July 28, 2010
Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage |
The Motley Fool
September 27, 2011
Brian Orelli |
Promising Results, But It's Still Early Aeterna Zentaris' investors got a bit of good news yesterday while they wait for phase 3 data for the company's colorectal cancer drug perifosine. |
The Motley Fool
August 30, 2011
Brian Orelli |
Aeterna Zentaris Passes Its Test AEZS-130, its diagnostic test for adult growth hormone deficiency, looks good. |
The Motley Fool
September 2, 2009 |
2 Stocks Hitting High Notes These stocks are reaching for the stars. Golden Star Resources Ltd... Jos. A. Bank Clothiers... etc. |
BusinessWeek
October 6, 2003
Lewis Braham |
Where Is Gold Going? How much higher can gold rise? Quite a lot, believes John Hathaway, portfolio manager of Tocqueville Gold Fund. |
The Motley Fool
November 11, 2011
David Williamson |
Roundtable: 5 Must-Watch Stocks Highlighting companies experts are watching around the office. |
The Motley Fool
January 6, 2012
Brian Orelli |
Don't Read Too Much Into This Partnership While the partnership is not a sign that Roche will buy Aeterna Zentaris, there's no doubt that the development of AEZS-108 makes the biotech a more attractive takeout candidate. |
The Motley Fool
May 24, 2007
Mike Havrilla |
A New Era at AEterna A strong balance sheet and a pair of promising products underlie optimism for the biopharmaceutical's future prospects. |
The Motley Fool
November 28, 2011
Brian Orelli |
Breaking Down a Biotech Press Release Aeterna Zentaris: FDA Grants IND to Investigator at Baylor College of Medicine for Phase 2A Trial with AEZS-130 in Cancer Cachexia. That sure is a mouthful. Let's see if we can break it down. |
The Motley Fool
December 23, 2011
Brian Orelli |
Geron's Hurry-Up-and-Wait Strategy Clinical trials started, now the waiting begins. |
The Motley Fool
January 18, 2012
Brian Orelli |
2 High-Flying Biotechs Face a New Hurdle The next number-one concern for Aeterna Zentaris' and Keryx's investors should be whether the drug passes its clinical trial. |
The Motley Fool
September 23, 2004
W.D. Crotty |
Striking Value in Small Gold Stocks As gold nears a multiyear high, you can pan for some smaller stocks that are well off their highs. |
The Motley Fool
February 8, 2011
Christopher Barker |
5 Imminent Catalysts for Gold Stocks Identifying the major coiled springs behind the next big surge for gold mining stocks. |
The Motley Fool
November 23, 2011
Brian Orelli |
I Was Wrong About Dendreon But maybe not in the long term. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
November 29, 2005
W.D. Crotty |
Gold's $500, But Where's the Excitement? At the end of the day, the gold companies are poised to reap the benefits of higher gold prices, at least for the time being. Investors, though, have already priced that exciting news into gold stock prices. |
The Motley Fool
August 15, 2011
Jim Royal |
6 Wild Bets on Biotech Riches The most interesting biotech tickers. |
The Motley Fool
October 25, 2006
Tim Beyers |
Who's Buying Now? Sometimes insiders are buying for all the right reasons. Who's buying now? General Electric... HEICO... Kinder Morgan... Sealy Corp... Universal Security Instruments... etc. |
The Motley Fool
December 31, 2011
Brian Orelli |
3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012. |
The Motley Fool
June 24, 2010
Christopher Barker |
China Strikes at the Heart of Gold Coeur d'Alene Mines scores a contract that offers a window into Chinese gold demand. |
The Motley Fool
December 6, 2011
Rick Aristotle Munarriz |
2013 Is Closer Than You Think Some prolific stocks are cheaper than you think. |
The Motley Fool
December 2, 2010
Esterhuizen & Sellitti |
Heading for the Exit: 7 Gold Stocks Being Sold by the Smart Money If you think big money managers and celebrity investing gurus are the only ones who stand to profit off a gold rally, guess again. |
The Motley Fool
June 14, 2010
Nathan Alderman |
Ask the Fool: Is Gold a Bubble? Is gold the new long-term king of commodities, or will its reign come crashing down when we least expect it? A Motley Fool panel debates the merits of shiny yellow metal. |
The Motley Fool
October 21, 2010
Alex Dumortier |
One More Reason to Be Bullish on Gold Dollar-rich, South Korea is looking at gold. |
The Motley Fool
February 21, 2007 |
Sealy Soars: Fool by Numbers The mattress maker released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
